Cambridge, UK;  19th November 2020.

Atlantic Healthcare plc (Atlantic Healthcare), the specialist gastrointestinal (GI) pharmaceutical company focused on acquiring, developing and commercializing therapies that address unmet patient needs and rare diseases, today announces the appointment of Allan Cambridge as Interim Chairman and Non-Executive Director.

Allan Cambridge is a highly respected healthcare professional with extensive board and CEO experience in the pharmaceutical and biotech sectors. Allan will lead the board through the next stage of the company’s development and appointment of a long-term Chairman.

A qualified pharmacist, Allan was part of the management team buyout of Evans Medical from Glaxo Pharmaceuticals (later GSK) and its later sale to Medeva for £87.5million. While at Wyeth Laboratories, he was member of the senior leadership team which quadrupled the UK sales to £550million and served as a senior member of the ex-US, international M&A and licensing team.

As a Senior Management Consultant at Deloitte & Touche, Allan advised Du Pont Merck Pharmaceuticals on establishing its European business and the European Commission on establishing the European Medicines Agency (EMA). He was also a Board member of the ABPI (Association of British Pharmaceutical Companies).

Allan played a key role at Alizyme plc, a biotechnology company specialising in gastroenterology, with setting up licensing agreements with Takeda Pharmaceutical Company Ltd and Prometheus, Inc. As CEO of biopharmaceutical company Lipoxen Technologies, now Xenetic Biosciences, Inc (NASDAQ:XBIO), he led its transformation into a focused commercial organization. More recently Allan was a senior executive at the GI company Tillotts Pharma, part of the Japanese Zeria Group.

Allan was one of the co-founding directors of Atlantic Healthcare.

Commenting on this announcement Allan said: “Atlantic Healthcare is at an exciting point in its development. Toby and the team have worked hard on both the clinical and commercial fronts to position the company for its next stage of growth. I am excited to join and lead the Board to support him and the team to deliver this.”

Andrew Boyce, in standing down as Interim Chairman said: “Allan is a veteran of the pharmaceutical industry with a long career based on successfully developing international pharmaceutical businesses, including gastroenterology. We are delighted to have Allan bring his expertise and experience to further strengthen the Atlantic Healthcare Board.”

~ ENDS ~

About Atlantic Healthcare

Atlantic Healthcare plc ( is a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases.

 The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug in development for ulcerative colitis and Crohn’s disease, and renzapride, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders, including patients with Cystic Fibrosis and Systemic Scleroderma.

Led by an experienced international Board and Leadership Team who have deep roots and a proven track record in the pharmaceutical industry, Atlantic Healthcare plans to commercialize its products itself in the U.S. and Europe and through partnerships and licensing with established pharmaceutical companies in the rest of the world.

Forward Looking Statements

While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.


For more information about Atlantic Healthcare, investment, alicaforsen or renzapride, please contact:

Adam Michael (Head of Communications)

+44 1799 512 055

+44 777 588 1813


Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal

+44 20 3709 5700